Compare iShares Core MSCI EAFE ETF (IEFA) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Stryker Corporation — how do they compare? iShares Core MSCI EAFE ETF trades at $100.96, while Stryker Corporation trades at $345.64 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| IEFA | SYK | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $101.09 | $394.34 |
52-Week Low | $84.72 | $282.58 |
Market Cap | — | $133.54B |
Enterprise Value | — | $145.01B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $100.895, up 0.36% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The fund focuses on developed international markets excluding the U.S. and Canada, offering diversification benefits and a dividend yield of 3.30% as noted by The Motley Fool on June 13, 2026. Recent news highlights its cost efficiency compared to peers like EFA, with an expense ratio of 0.07%.
Outlook is positive due to defensive inflows and Fed cut potential, but risks include capped upside from covered call strategies and concentration in non-U.S. markets. Analyst sentiment is mixed, with some favoring broader ETFs like VXUS for higher returns.
Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.
Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
